Purpose, policy and the future of clinical trials: Noxopharm CEO on what’s next for Australian biotech

As the world marks Clinical Trials Day (20 May), Dr Gisela Mautner, CEO of ASX-listed biotech Noxopharm, brings a bold and future-focused perspective to the conversation.

In this Health Industry Hub podcast, Dr Mautner delves into how the theme Powered by Purpose is more than just a nod to the human stories behind the science. It’s a statement of intent that fuels every decision and is reflected in the company’s latest research milestones, including its first-in-human clinical trial.

The conversation also turns political, as Dr Mautner reflects on the re-election of the Albanese Government and the implications of a reshuffled cabinet. She points to several key policy levers as critical to the survival and success of Australian biotech companies operating in a global landscape.

Australia’s clinical trials sector, recently valued at $1.6 billion in annual economic impact, is also under the microscope. While Dr Mautner celebrates the country’s reputation for high-quality research and patient care, she doesn’t shy away from addressing the cracks that threaten its long-term competitiveness.

Another focus of the discussion is the evolving role of the patient in clinical research. Dr Mautner argues that real progress requires more than enrolment numbers; it demands diversity and the amplification of patient voices from trial design to outcomes measurement. This shift isn’t just ethically sound, it’s scientifically necessary.

Looking ahead, Dr Mautner maps out the seismic shifts poised to transform the clinical trials landscape over the next five years.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.